National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health -
Clinical Trials at NIH Home

Investigator Profiles

C. Ola Landgren, M.D., Ph.D.

C. Ola Landgren, M.D., Ph. D.

Medical Oncology Branch and Affiliates
Head, Multiple Myeloma Section
Senior Investigator

National Cancer Institute
9000 Rockville Pike
Building 10, Room 13N240
Bethesda, MD 20892

Phone: 301-496-0670
Fax: 301-402-0172

Dr. Landgren received his M.D. in 1995 from the Karolinska Institute in Stockholm, Sweden. Following clinical training as a hematology/internal medicine specialist physician, he earned a Ph.D. with a focus on diagnostics and prognostics in Hodgkin lymphoma in 2002 at Karolinska Institute. He then served as an attending physician at Karolinska and conducted clinical research on lymphoproliferative malignancies and related precursors. He came to the National Cancer Institute’s (NCI) Division of Cancer Epidemiology and Genetics (DCEG) in 2004, where he served as an Investigator before he joined the Medical Oncology Branch.

Dr. Landgren's major research interests are in the treatment, causation, diagnostics and prognostics, and natural history of multiple myeloma and its precursor condition, monoclonal gammopathy of undetermined significance (MGUS). He also studies related hematologic malignancies and their precursor states, including chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis (MBL); Waldenstrom’s macroglobulinemia, and IgM MGUS, as well as myeloproliferative neoplasms. His research focuses on treatment-, host-, disease-, and immune-related factors in the pathway from precursor to full-blown malignancy and their relation to outcome.

Dr. Landgren's Clinical Trial(s):

NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with MGUS, smoldering myeloma, and multiple myeloma. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.

Videocast/Podcast Videocast/Podcast Details:

The quality of these videocasts is dependent on the speed of your Internet connection. Many videocasts are streamed directly to your computer by software on the NIH VideoCasting Web site. Others require that you have a standalone player installed on your computer to handle the streaming. If you do not have a standalone player installed or if you are having problems viewing the videocast, please visit

CC Grand Rounds: (1) Therapeutic Gene Delivery: Using Hematopoietic Stem Cells in Sickle Cell Disease (2) Multiple Myeloma and Its Precurser (MGUS): Looking into the Future

Speaker(s): John F. Tisdale, M.D., Senior Investigator, Molecular and Clinical Hematology Branch, NHLBI
Ola Landgren, M.D., Ph.D., Investigator, Medical Oncology Branch, Center for Cancer Research, NCI

April 16, 2010

60 minutes

Eradicating Multiple Myeloma

Speaker(s): C. Ola Landgren, M.D., Ph.D., Head, Multiple Myeloma Section, Medical Oncology Branch and Affiliates, NCI

September 15, 2010

3 minutes, 32 seconds

NIH Director's Seminar Series: Multiple Myeloma and its Precursor Disease: the Future is Already Here

Speaker(s): C. Ola Landgren, M.D., Ph.D. Head, Multiple Myeloma Section, Medical Oncology Branch and Affiliates, NCI

April 20, 2012

50 minutes

Some of the resources above require the use of a standalone player: Download Free RealPlayer External link—please read our disclaimer.

Back to Top
Health and Human Services National Institutes of Health National Cancer Institute